VivoSim Labs Signs Seven-Figure Agreement with a Top-10 Global Pharmaceutical Company; Expects to Exceed Its 500%+ Revenue Growth Guidance for Fiscal 2027
Key Highlights
- ➤VivoSim Labs (VIVS) signs seven-figure NAMkind™ agreement with top-10 global pharmaceutical company
- ➤Fiscal 2027 revenue expected to exceed 500%+ growth guidance
- ➤Agreement revenue expected in fiscal Q3 and Q4 ending Dec. 31 and March 31
- ➤Chemveda Life Sciences collaboration targets AI-designed compounds; first programs expected this quarter
- ➤FDA issued final rule clarifying non-animal methods may test drug and biologic safety
Expert Statements
Keith Murphy, Executive Chairman of VivoSim Labs
“In July we told shareholders revenue would grow more than 500% this fiscal year. The quarterly report we filed last week shows both toxicology businesses growing, and this agreement on its own is expected to take us past that number. What matters more is what comes after it. A top-10 company has gone from evaluating our human liver and intestine models to paying for program work, and we expect its regular testing to follow. Other large customers are moving the same way.”
Tony Lialin, Chief Commercial Officer of VivoSim Labs
“Both toxicology service lines grew in the September quarter, with orders from large pharmaceutical companies and from smaller biotechs. A large customer comes in through an evaluation, then a paid program, then its standing workflow. This Customer is at the second step, and we have others at the first.”
SAN DIEGO, Nov. 19, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3D human cellular models for preclinical safety and efficacy testing, today announced a seven-figure agreement with a top-10 global pharmaceutical company (the “Customer”) for NAMkind™ testing services. With this agreement, the Company expects fiscal 2027 revenue to exceed the guidance of 500%+ growth it issued on July 15, 2026. * The agreement covers NAMkind™ liver and intestinal toxicology testing, with work already underway. Revenue under the agreement is expected to be recognized in VivoSim’s fiscal Q3 and Q4, ending Dec. 31 and March 31, respectively. * After this program, VivoSim anticipates that NAMkind™ testing will become part of the Customer's regular flow of ongoing preclinical work. * The Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed on November 12, shows growth in both its liver toxicology and intestinal toxicology businesses. * Growth came from both large pharma and smaller customers. Other current and future customers are also expected to move toward full integration of NAMkind™ testing into their workflows How a Large Customer Adopts a New Test
Get started
Create a free account to read the full story.
